Connection

Naphak Modhiran to Adjuvants, Immunologic

Back to Details
This is a "connection" page, showing publications Naphak Modhiran has written about Adjuvants, Immunologic.
Naphak Modhiran
Connection Strength
0.110
Adjuvants, Immunologic
  1. Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Infect Dis. 2021 10; 21(10):1383-1394.
    View in: PubMed
    Score: 0.110
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.